Dose Escalation Reverses Antibody Formation and Loss of Response in Children with Inflammatory Bowel Disease Treated with Adalimumab

Abstract In this study, we describe 4 children with inflammatory bowel disease (IBD) who had a reversal of adalimumab antibodies (AA) and regained clinical response following dose escalation of adalimumab. We observed in our cases that all of them benefitted from adalimumab dose escalation in terms of achieving clinical and laboratory remission as well as achieving desirable adalimumab trough level and reversal of adalimumab antibodies. Keywords: Inflammatory bowel disease, adalimumab antibodies, dose escalation.